US FDA’s Rejection Letter Reveals New Barriers Sanofi Must Overcome for Tolebrutinib

 
• By Manas Mishra
  
The FDA has published a redacted complete response letter for Sanofi’s tolebrutinib as part of its new push for increased transparency. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews